扩大乙型肝炎治疗指南的影响:建模与经济影响分析
该建模分析评估韩国扩大慢性乙型肝炎治疗标准对至2035年疾病负担与经济影响。
要点
- 所有场景假设治疗70%的符合条件者。
核心结论
- 简化和扩大慢性乙型肝炎的治疗资格可挽救许多生命,并在高诊断率下具有高度成本效益。
- 这些动态国家层面数据可能为其全球应用提供新见解。
研究设计与样本
- 研究使用动态国家层面数据,估计韩国至2035年三种增量场景相比基础病例的肝细胞癌发生率、总死亡率和经济影响。
主要发现
- 2020年估计有1,409,000例慢性乙型肝炎病例,多数出生于1995年前。
- 所有场景假设治疗70%的符合条件个体。
- 第一个场景取消肝硬化患者的病毒载量限制,可避免13,000例肝细胞癌并挽救11,800例生命。
- 第二个场景将非肝硬化患者的丙氨酸氨基转移酶(ALT)限制降至正常上限,可避免26,700例肝细胞癌并挽救23,300例生命。
- 最后一个场景取消对病毒载量≥2000 IU/ml的非肝硬化个体治疗时ALT和HBeAg的限制,可避免43,300例肝细胞癌并挽救37,000例生命。
关键数值与推荐
- 第一个场景:取消肝硬化患者的病毒载量限制,避免13,000例肝细胞癌,挽救11,800例生命。
- 第二个场景:非肝硬化患者ALT限制降至正常上限,避免26,700例肝细胞癌,挽救23,300例生命。
- 第三个场景:取消病毒载量≥2000 IU/ml的非肝硬化个体治疗时ALT和HBeAg限制,避免43,300例肝细胞癌,挽救37,000例生命。
- 所有场景假设治疗70%的符合条件个体,且均具高度成本效益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients receive antiviral treatment globally. The complexity and strictness of the current clinical practice guidelines may limit expanding the treatment coverage for CHB. AIMS: To examine the impact of expanding treatment criteria on future disease burden in Korea, a hepatitis B virus (HBV) endemic country with high diagnostic rates. MATERIALS: Dynamic country-level data were used to estimate the HCC incidence, overall mortality and economic impact of three incremental scenarios compared to the base case in Korea through 2035. RESULTS: In 2020, 1,409,000 CHB cases were estimated, with the majority born before 1995. All scenarios assumed treating 70% of eligible individuals. The first scenario removed viral load restrictions in cirrhotic patients, which would avert 13,000 cases of HCC and save 11,800 lives. The second scenario, lowering the alanine aminotransferase (ALT) level restriction to the upper limit of the normal in non-cirrhotic patients, would avert 26,700 cases of HCC and save 23,300 lives. The last scenario removed the restriction by ALT and HBeAg in treating non-cirrhotic individuals with a viral load of ≥2000 IU/ml, which would avert 43,300 cases of HCC and save 37,000 lives. All scenarios were highly cost-effective. CONCLUSIONS: Simplifying and expanding treatment eligibility for CHB would save many lives and be highly cost-effective when combined with high diagnostic rates. These dynamic country-level data may provide new insights for their global application.
引用
- Lim YS, Ahn SH, Shim JJ, et al. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther. 2022. PMID: 35614532. doi:10.1111/apt.17052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。